MAPT and Alzheimer disease: Measurements of Abeta1–42 (controls – 919 ± 194 pg/mL, MCI – 715 ± 402 pg/mL, AD – 568 ± 188 pg/mL), h-tau (controls – 215 ± 73 pg/mL, MCI – 488 ± 203 pg/mL, AD – 867 ± 378 pg/mL), and p-tau (controls – 37 ± 10 pg/mL, MCI – 66 ± 22 pg/mL, AD – 102 ± 27 pg/mL) exhibited highly significant shifts in the groups.